A drug-reformulation platform giving existing molecules a new therapeutic life.

Through long-acting intranasal delivery, designed for chronic respiratory and CNS diseases.

Mastering innovation to enhance patients and caregivers quality of life.

Scroll down
UNMET NEEDS / PAIN POINTS

Where current treatments fall short

A massive global burden

  • Allergic rhinitis — 1.4 billion patients worldwide¹
  • Chronic rhinosinusitis — 900 million patients impacted²
  • CNS disorders — 35 million patients (schizophrenia + Parkinson’s)³

A treatment gap that persists

  • Non-compliance — 85% of allergic rhinitis patients are not compliant with their daily treatment⁴
  • Non-response — 20–25% of CRS patients do not respond to first-line treatment⁵
  • Drug-delivery barriers — major obstacles (BBB, hepatic first-pass) limit CNS treatment efficacy

<

About us

Dianosic designs transformative long-acting resorbable intranasal solid-dosage forms to overcome the delivery challenges of chronic respiratory and CNS therapies.

We identify unmet clinical needs with healthcare professionals and collaborate with them to offer disruptive solutions to the patients, the medical community and the society as a whole.

Learn more
Our ambitions

The administration of long-acting intranasal solid dosage forms enables the treatment of multiple respiratory diseases at low doses, delivered directly at the site of action.

Addresses a major challenge in patient adherence to treatment.

For central nervous system disorders, this approach has the potential to overcome major drug-delivery barriers by exploiting the “nose-to-brain” pathway.

Excellent nasal retention without compromising patient comfort or quality of life.

Our Science

Dianosic develops a platform of cutting-edge intranasal solutions based on a proprietary know-how in drug-eluting, long-acting, resorbable polymer inserts. Our DIAXX platform enables sustained local, systemic and nose-to-brain drug delivery currently developed across two therapeutic areas: chronic respiratory diseases (DIA01-R, DIA02-S) and central nervous system disorders (DIA03-NTB)

Learn more
Pipeline

Discover our complex intranasal formulations and advanced drug-delivery solutions for chronic respiratory diseases and central nervous system disorders.

Three programs. Three stages of development. One platform. Built on DIAXX, our pipeline addresses chronic respiratory diseases (DIA01-R, Phase I-ready in 2026; DIA02-S, preclinical) and central nervous system disorders (DIA03-NTB, discovery), targeting more than 2 billion patients worldwide.

DIA01-R

Chronic Allergic Rhinitis (CAR) | Clinical Stage -- Phase I-ready (2026)

DIA02-S

Chronic RhinoSinusitis (CRS) | labelling extension of DIA01-R | Preclinical

DIA03-NTBS

Schizophrenia (Nose-to-Brain) (CNS) | Discovery / proof-of-concept

Learn more

Partner with us

Our DIAXX platform de-risks your formulation work and preclinical in vivo validation, accelerating time-to-proof-of-concept for your molecule. Whether through classic co-development, out-licensing, or strategic alliance, we offer flexible partnership models — from integrating your API into our proprietary intranasal insert to accessing our internal respiratory and CNS programs.

Learn more
News & Investors See all news

Stay tuned and follow us on social media.

Oct 10, 2024

Dianosic X WiSEED: Fundraising

See more
Feb 12, 2024

Dianosic shortlisted for the “Trophées des Entreprises Alsace 2024” award

See more
Learn more